Evidence map›Paper›PMID 33600921›Full record

ReviewToxicology letters2021

Ocular toxicity of mustard gas: A concise review.

Allison Fuchs, Elizabeth A Giuliano, Nishant R Sinha, Rajiv R Mohan

Abstract readReview
In one paragraph

Review in Toxicology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. BRD4 inhibition mitigates acute and chronic corneal injury following topical nitrogen mustard exposure.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. Fenofibrate microemulsion eyedrops for treating nitrogen mustard induced corneal injury.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Allison FuchsOne-Health Vision Research Program, Departments of Veterinary Medicine & Surgery and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Elizabeth A GiulianoHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States; One-Health Vision Research Program, Departments of Veterinary Medicine & Surgery and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Nishant R SinhaHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States; One-Health Vision Research Program, Departments of Veterinary Medicine & Surgery and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Rajiv R MohanHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States; One-Health Vision Research Program, Departments of Veterinary Medicine & Surgery and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States; Mason Eye Institute, School of Medicine, University of Missouri, Columbia, MO, United States. Electronic address: mohanr@health.missouri.edu.

Funding

Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur MustardU01EY031650 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2020 to 2024
$3.7M
Novel approaches for corneal haze/fibrosis eliminationR01EY030774 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2019 to 2022
$1.5M
Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur MustardR21EY030234 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2018 to 2019
$426k
Targeted Gene Therapy and Nanomedicine Approaches to Treat Corneal DiseasesI01BX000357 · VA · HARRY S. TRUMAN MEMORIAL VA HOSPITAL · PI Rajiv Ravindra Mohan · 2009 to 2026
–
BLR&D Research Career Scientist Award Application (Renewal)IK6BX005646 · VA · HARRY S. TRUMAN MEMORIAL VA HOSPITAL · PI MOHAN, RAJIV RAVINDRA · 2021 to 2025
–
BLRD VA I01 BX000357BLRD VA IK6 BX005646NEI NIH HHS R01 EY030774NEI NIH HHS R21 EY030234NEI NIH HHS U01 EY031650
6 · The paper itself

Abstract

Sulfur mustard (SM) is a chemical warfare agent that has been used throughout recent history and remains a threat today. Exposed soldiers and civilians experience a variety of symptoms primarily in the respiratory system, skin, and eyes. The ocular tissues are highly sensitive to damage by SM and undergo unique manifestations of acute, chronic, and delayed complications that can persist for months and years after exposure. The mechanisms of this unique mustard gas keratopathy are still not fully understood and animal models for the study of this disease are discussed. Recent advances in mechanisms of injury are included in this review. Ophthalmic manifestations of SM injury including persistent epithelial defects, limbal stem cell deficiency, corneal neovascularization, dry eye, and corneal opacification have been reported. A wide variety of medical and surgical therapies have been studied and are reviewed here along with potential future therapies.

Indexed as

Chemical Warfare AgentsDrug Administration ScheduleEye DiseasesHumansMustard GasChemical Warfare AgentsMustard GascorneaCorneal stromal injuryMustard gas keratopathySulfur mustard

Identifiers

PMID33600921
PMCPMC9206441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.